Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics' stock price has declined significantly over the past six months. The termination of the Pfizer collaboration for giroctocogene fitelparvovec led to a stock price drop. A dilutive equity offering in February 2026 caused the stock to tumble. Positive data from the Fabry disease study and progress on the BLA submission did not prevent stock pressure. Q4 and full-year 2025 financial results revealed a wider loss than anticipated, negatively impacting investor confidence. Management expressed concerns about the company's ability to continue as a going concern and potential Nasdaq delisting.

Demand for Sangamo Therapeutics' products and services is not subject to traditional seasonal fluctuations. Demand is driven by patient identification, regulatory approvals, the curative nature of treatments, disease prevalence, and clinical trial progress and partnerships. Demand is influenced by scientific breakthroughs, clinical trial outcomes, regulatory milestones, and the ongoing identification of eligible patients, rather than calendar-based seasonality.

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company focused on developing treatments for severe genetic and rare diseases. The company utilizes its proprietary zinc finger protein (ZFP) technology platforms, including gene therapy, cell therapy, genome editing, and genome regulation, to create genomic medicines. Sangamo's lead asset, isaralgagene civaparvovec (ST-920) for Fabry disease, is in Phase 1/2 clinical trials with a BLA submission planned for late 2025. Other programs target conditions like chronic neuropathic pain and prion disease, and partnered programs address hemophilia A, oncology, ALS/FTD, and Huntington's Disease. The company generates revenue through collaboration and licensing agreements with pharmaceutical partners.

Sangamo Therapeutics is headquartered in Brisbane, California, with main operations in Richmond, California, United States. While primarily based in the U.S., its partnerships with global pharmaceutical firms suggest a broader global reach for the development and potential commercialization of its genomic medicines.

Sangamo Therapeutics emphasizes ethical conduct, integrity, and DEI. There have been no widely reported events or controversies significantly impacting its brand reputation in the past year, beyond market reactions to clinical and financial news.

Sangamo Therapeutics has significant institutional ownership, with 113 institutional owners holding 63,037,579 shares as of April 10, 2026. Major institutional owners include Vanguard Group Inc., Renaissance Technologies Llc, and BlackRock, Inc. Biogen Inc. is the largest individual shareholder, owning 17.65 million shares, representing 4.26% of the company.